Sotera Health (NASDAQ:SHC) Issues FY 2026 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.950-1.010 for the period, compared to the consensus estimate of 0.950. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Sotera Health Trading Down 0.3%

SHC opened at $18.86 on Friday. The firm’s fifty day moving average is $17.13 and its two-hundred day moving average is $16.33. The firm has a market cap of $5.38 billion, a PE ratio of 33.09 and a beta of 1.77. Sotera Health has a twelve month low of $12.94 and a twelve month high of $19.85. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.54 and a current ratio of 2.80.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. The company had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The firm’s revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities research analysts anticipate that Sotera Health will post 0.87 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SHC shares. UBS Group set a $19.00 price objective on Sotera Health in a report on Wednesday, June 24th. Weiss Ratings upgraded shares of Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 9th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of Sotera Health in a research report on Friday. Citigroup raised their price objective on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen lowered Sotera Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and an average target price of $21.50.

Insider Activity at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.36% of the stock is currently owned by corporate insiders.

Sotera Health News Roundup

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Institutional Trading of Sotera Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its holdings in shares of Sotera Health by 10.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company’s stock worth $127,000 after buying an additional 705 shares in the last quarter. Federated Hermes Inc. boosted its stake in Sotera Health by 6.0% in the fourth quarter. Federated Hermes Inc. now owns 16,676 shares of the company’s stock valued at $294,000 after buying an additional 944 shares in the last quarter. First Citizens Bank & Trust Co. grew its position in Sotera Health by 1.5% in the fourth quarter. First Citizens Bank & Trust Co. now owns 66,266 shares of the company’s stock valued at $1,169,000 after acquiring an additional 970 shares during the last quarter. Legal & General Group Plc grew its position in Sotera Health by 0.5% in the third quarter. Legal & General Group Plc now owns 255,526 shares of the company’s stock valued at $4,019,000 after acquiring an additional 1,252 shares during the last quarter. Finally, California State Teachers Retirement System raised its stake in Sotera Health by 0.9% during the third quarter. California State Teachers Retirement System now owns 145,318 shares of the company’s stock worth $2,286,000 after acquiring an additional 1,315 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.